MedTrace Logo

Intermittent Fasting as a Means to Lose Fluid Overload and Weight in Complicated Obesity

NCT04193995 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-06-02

No results posted yet for this study

Summary

To examine the feasibility of intermittent fasting (36h, twice a week, unlimited salt and calorie-free fluid consumption), over three months, on body weight and composition in complicated obesity in whom age and medical complexity exclude the possibility of bariatric surgery.

Conditions

  • Intermittent Fasting
  • Obesity, Morbid
  • Comorbidities and Coexisting Conditions
  • Weight Loss
  • Fluid Retention

Interventions

BEHAVIORAL

Intermittent fasting

There are two 36h fasting periods (FP) every week, over a 12week period. Free access to water is allowed; two cups of tea or coffee are also allowed. Each 36h FP begins after the last meal, which is consumed no later than 2000h on the preceding nights. Fasting days are Sunday and Wednesday, and fasting is terminated at 0800 on Monday and Thursday. Medications may be adjusted as needed during these visits, and this is reconsidered and may be further adjusted after the receipt of the blood tests results later during the day. Adjustments based on lab results are discussed with the patients during the clinic visit or later on the same day. Also, dietary needs are addressed by the physician and /or the dietician, during the clinic visit. As of week 3 through week 12, clinic visit is reduced to once a week, on Thursdays.

Sponsors & Collaborators

  • Tel-Aviv Sourasky Medical Center

    lead OTHER_GOV

Principal Investigators

  • Naftali Stern, MD · Tel-Aviv Sourasky Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2020-12-31
Completion
2021-04-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04193995 on ClinicalTrials.gov